Intranasal DDAVP: biological and clinical evaluation in mild factor VIII deficiency

Haemostasis. 1991;21(5):273-7. doi: 10.1159/000216236.


We report a study undertaken to test the biological effect of intranasal 1-deamino-8-D-arginine vasopressin (DDAVP) and its efficacy in the treatment of bleedings in patients with mild factor VIII deficiency. The biological study was carried out in 20 patients: an increase of factor VIII:C and von Willebrand factor antigen levels was observed after inhalation of DDAVP at average post/pre inhalation ratios of 2.80 and 1.72, respectively. No relevant alterations of fibrinolysis were noted. In fact, we only observed a simultaneous increase of tissue plasminogen activator and plasminogen activator inhibitor, without modification of D-dimer. In 10 cases intranasal DDAVP has been used in the prevention or in the treatment of bleeding complications: no bleedings were observed.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Intranasal
  • Adolescent
  • Adult
  • Child
  • Deamino Arginine Vasopressin / administration & dosage
  • Deamino Arginine Vasopressin / therapeutic use*
  • Drug Evaluation
  • Factor VIII / analysis
  • Fibrinolysis
  • Hemophilia A / blood
  • Hemophilia A / therapy*
  • Hemorrhage / prevention & control*
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / therapeutic use*
  • Middle Aged


  • Immunologic Factors
  • Factor VIII
  • Deamino Arginine Vasopressin